Our team is happy and proud to have been voted as the winner for pitching our MTHFD1/2 inhibitor program.
https://www.linkedin.com/feed/update/urn:li:activity:6948268990171365376
One-carbon Therapeutics AB announces the addition of multiple international experts to its Scientific Advisory Board
Professor Johann de Bono, Head of the Division of Clinical
